Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival
Predicts overall survival in AML patients with relapsed/refractory disease undergoing myeloablative transplant.
Use in patients with relapsed or refractory active AML for whom hematopoietic stem cell transplant (HSCT) is being considered. Do not use in patients with chronic myelogenous leukemia (CML) in blast crisis.
0 points
42 %
Michel Duval, MD, is the medical director of the hematopoietic transplantation and Cell Therapy Program at the Charles-Bruneau Cancer Center, at the Sainte-Justine University Hospital Center in Montreal, Canada. He is also the co-chief of the hemato-oncology department at the Centre Hospitalier Universitaire Sainte-Justine. Dr. Duval’s research focuses primarily on immunotherapy of childhood cancers and cord blood transplant immunology.
- Joseph Maakaron, MD